Loading...
XTSXMPH
Market cap6mUSD
Dec 23, Last price  
0.89CAD
1D
0.00%
1Q
-11.88%
Jan 2017
-91.36%
Name

Medicure Inc

Chart & Performance

D1W1MN
XTSX:MPH chart
P/E
—
P/S
0.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-8.82%
Rev. gr., 5y
-5.71%
Revenues
22m
-5.94%
459,197299,7375,944,7302,247,1294,792,5133,317,0733,628,2744,796,8112,602,7005,050,7619,024,67922,083,12837,778,47127,132,83229,109,36520,173,00011,610,00021,744,00023,065,00021,694,000
Net income
-922k
L
-14,865,910-12,607,074-31,703,386-57,402,521-13,315,827-5,532,506-2,014,10923,385,779-2,574,304-1,638,9522,049,5931,668,42927,657,47443,420,8843,925,639-19,786,000-6,845,000-727,0001,365,000-922,000
CFO
2m
+13.73%
-12,067,515-12,678,498-25,246,653-41,864,640-10,418,139-1,452,809477,479417,289-990,478110,880473,969142,7956,410,81121,923,132742,273-14,641,000-2,240,0003,989,0001,828,0002,079,000
Earnings
Apr 07, 2025

Profile

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
URL
https://www.medicure.com/
IPO date
Mar 30, 1999
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
21,694
-5.94%
23,065
6.08%
21,744
87.29%
Cost of revenue
22,548
21,872
23,837
Unusual Expense (Income)
NOPBT
(854)
1,193
(2,093)
NOPBT Margin
5.17%
Operating Taxes
25
20
(32)
Tax Rate
1.68%
NOPAT
(879)
1,173
(2,061)
Net income
(922)
-167.55%
1,365
-287.76%
(727)
-89.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
56
BB yield
-0.38%
Debt
Debt current
315
346
380
Long-term debt
773
1,352
1,958
Deferred revenue
Other long-term liabilities
696
Net debt
(5,281)
(3,159)
(1,356)
Cash flow
Cash from operating activities
2,079
1,828
3,989
CAPEX
(310)
(818)
Cash from investing activities
(270)
(310)
(2,694)
Cash from financing activities
(297)
(355)
(316)
FCF
284
379
(1,743)
Balance
Cash
6,369
4,857
3,694
Long term investments
Excess cash
5,284
3,704
2,607
Stockholders' equity
9,173
10,529
7,982
Invested Capital
15,156
18,090
17,555
ROIC
6.58%
ROCE
5.47%
EV
Common stock shares outstanding
10,436
10,436
10,251
Price
1.40
38.61%
1.01
9.78%
0.92
-22.69%
Market cap
14,611
38.61%
10,541
11.76%
9,431
-25.83%
EV
9,330
7,382
8,075
EBITDA
1,316
3,248
1,052
EV/EBITDA
7.09
2.27
7.68
Interest
10
23
38
Interest/NOPBT
1.93%